文献速递头颈与中枢神经肿瘤

剂量递增调强放疗未改善局部晚期喉癌/下咽癌局部区域控制:ART DECO III期随机对照试验

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
PubMed 文献 · Eur J Cancer · 2021-07-10

ART DECO研究为III期开放标签随机对照试验,纳入276例局部晚期喉癌或下咽癌患者,1:1随机接受剂量递增调强放疗(DE-IMRT)或标准剂量调强放疗(ST-IMRT)。主要终点为局部区域失败时间,中位随访47.9个月,DE-IMRT组局部区域失败率30.4%,ST-IMRT组27.5%,调整亚风险比1.16(95%CI 0.74-1.83,p=0.519),无获益证据。结论:DE-IMRT未改善局部区域控制。

要点

  • DE-IMRT较ST-IMRT未改善局部区域控制(调整sHR 1.16,p=0.519)。
  • DE-IMRT组急性2级咽黏膜炎发生率更高(42% vs 32%)。
  • 两组≥3级急性或晚期毒性发生率无差异。

核心结论

  • 在局部晚期喉癌或下咽癌患者中,剂量递增调强放疗(DE-IMRT)未改善局部区域控制。

研究设计与样本

  • 随机采用最小化算法,按中心、肿瘤部位、淋巴结状态和化疗使用平衡。
  • DE-IMRT:原发肿瘤67.2 Gy/28次,高危淋巴结56 Gy/28次;ST-IMRT:原发肿瘤65 Gy/30次,高危淋巴结54 Gy/30次。
  • 合适患者接受2周期同步顺铂化疗及最多3周期铂类诱导化疗。
  • 主要终点为局部区域失败时间,采用竞争风险方法按意向性治疗分析。

主要发现

  • 中位随访47.9个月(四分位距37.5-60.5),ST-IMRT组局部区域失败38/138(27.5%),DE-IMRT组42/138(30.4%)。
  • 调整亚风险比1.16(95%CI 0.74-1.83,p=0.519),无获益证据。
  • DE-IMRT组急性2级咽黏膜炎发生率高于ST-IMRT组(42% vs 32%)。
  • 两组≥3级急性或晚期毒性发生率无差异。
  • 预计划的中期无效性分析达到早期终止标准。

关键数值与推荐

  • DE-IMRT剂量:原发肿瘤67.2 Gy/28次,高危淋巴结56 Gy/28次。
  • ST-IMRT剂量:原发肿瘤65 Gy/30次,高危淋巴结54 Gy/30次。
  • 局部区域失败:ST-IMRT 27.5% vs DE-IMRT 30.4%,调整sHR 1.16(95%CI 0.74-1.83,p=0.519)。

临床怎么用

  • 对于局部晚期喉癌或下咽癌,不推荐常规采用本试验中的DE-IMRT方案以提高局部区域控制。
  • DE-IMRT可能增加急性2级咽黏膜炎,需关注支持治疗。

局限性

  • 试验因预计划中期无效性分析达到早期终止标准而提前关闭。
  • 中位随访47.9个月,长期疗效与晚期毒性需更长时间观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. METHODS: We performed a phase III open-label randomised controlled trial in patients with laryngeal or hypopharyngeal cancer (AJCC III-IVa/b, TNM 7). Patients were randomised (1:1) to DE-IMRT or standard dose IMRT (ST-IMRT) using a minimisation algorithm, balancing for centre, tumour site, nodal status and chemotherapy use. DE-IMRT was 67.2 gray (Gy) in 28 fractions (f) to the primary tumour and 56Gy/28f to at-risk nodes; ST-IMRT was 65Gy/30f to primary tumour and 54Gy/30f to at-risk nodes. Suitable patients received 2 cycles of concomitant cisplatin and up to 3 cycles of platinum-based induction chemotherapy. The primary end-point was time to locoregional failure analysed by intention-to-treat analysis using competing risk methodology. FINDINGS: Between February 2011 and October 2015, 276 patients (138 ST-IMRT; 138 DE-IMRT) were randomised. A preplanned interim futility analysis met the criterion for early closure. After a median follow-up of 47.9 months (interquartile range 37.5-60.5), there were locoregional failures in 38 of 138 (27.5%) ST-IMRT patients and 42 of 138 (30.4%) DE-IMRT patients; an adjusted subhazard ratio of 1.16 (95% confidence interval: 0.74-1.83, p = 0.519) indicated no evidence of benefit with DE-IMRT. Acute grade 2 pharyngeal mucositis was reported more frequently with DE-IMRT than with ST-IMRT (42% vs. 32%). No differences in grade ≥3 acute or late toxicity rates were seen. CONCLUSION: DE-IMRT did not improve locoregional control in patients with laryngeal or hypopharyngeal cancer. The trial is registered: ISRCTN01483375.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nutting CM, Griffin CL, Sanghera P, et al. Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. Eur J Cancer. 2021. PMID: 34256319. doi:10.1016/j.ejca.2021.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。